Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Failure to honor embargo policies (http://newsroom.heart.org/newsmedia/embargo-policy) will result in the abstract being withdrawn and barred from presentation.

Jump to

Abstract

Background and objective: Soluble ST2 (sST2), an interleukin (IL)-1 receptor family member, has been identified as a novel biomarker for cardiac stress. Although sST2 were reported to be elevated in acute Kawasaki disease (KD) and correlated with cardiac diastolic dysfunction, relation between sST2 levels and treatment resistance and risk of coronary artery abnormalities (CAAs) is not studied. The aim of this study is to evaluate clinical utility of sST2 in acute KD.